Hammersmith Hospital, London, UK
Clin Med (Lond). 2019 May;19(3):243-247. doi: 10.7861/clinmedicine.19-3-247.
Pulmonary embolism, despite being common, often remains elusive as a diagnosis, and clinical suspicion needs to remain high when seeing a patient with cardiopulmonary symptoms. Once suspected, diagnosis is usually straightforward; however, optimal treatment can be difficult. Risk stratification with clinical scores, biomarkers and imaging helps to refine the best treatment strategy, but the position of thrombolysis in intermediate risk (submassive) pulmonary embolism remains a grey area. Pulmonary embolism response teams are on the increase to provide advice in such cases. Direct oral anticoagulants have been a major advance in treatment this decade, but are not appropriate for all patients. Follow-up of patients with pulmonary embolism should be mandatory to determine duration of anticoagulation and to assess for serious long-term complications.
肺栓塞虽然常见,但作为一种诊断仍然难以捉摸,当看到有心肺症状的患者时,临床医生需要保持高度警惕。一旦怀疑,诊断通常很直接;然而,最佳治疗可能很困难。通过临床评分、生物标志物和影像学进行风险分层有助于完善最佳治疗策略,但溶栓治疗在中危(亚大面积)肺栓塞中的地位仍然存在争议。肺栓塞反应团队的增加为这种情况下提供了建议。直接口服抗凝剂是这十年治疗的重大进展,但并非所有患者都适用。肺栓塞患者的随访是强制性的,以确定抗凝时间并评估严重的长期并发症。